Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. by Baraldo, S. et al.
DOI 10.1378/chest.06-2819 
 2007;132;1733-1740; Prepublished online July 23, 2007; Chest
 
Leonardo M. Fabbri, Renzo Zuin and Marina Saetta 
Spiridione Garbisa, Piero Maestrelli, Alberto Papi, Massimo Miniati, 
Simonetta Baraldo, Erica Bazzan, Maria Elena Zanin, Graziella Turato,
 
 Periphery Is Related to COPD Progression
Matrix Metalloproteinase-2 Protein in Lung
 http://chestjournal.org/cgi/content/abstract/132/6/1733
and services can be found online on the World Wide Web at: 
The online version of this article, along with updated information
). ISSN: 0012-3692. http://www.chestjournal.org/misc/reprints.shtml(
of the copyright holder 
may be reproduced or distributed without the prior written permission 
Northbrook IL 60062. All rights reserved. No part of this article or PDF
by the American College of Chest Physicians, 3300 Dundee Road, 
2007Physicians. It has been published monthly since 1935. Copyright 
CHEST is the official journal of the American College of Chest
Copyright © 2007 by American College of Chest Physicians 
 on November 25, 2008 chestjournal.orgDownloaded from 
Matrix Metalloproteinase-2 Protein in
Lung Periphery Is Related to COPD
Progression*
Simonetta Baraldo, PhD; Erica Bazzan, PhD; Maria Elena Zanin, BSc;
Graziella Turato, PhD; Spiridione Garbisa, PhD; Piero Maestrelli, MD;
Alberto Papi, MD, FCCP; Massimo Miniati, MD; Leonardo M. Fabbri, MD, FCCP;
Renzo Zuin, MD; and Marina Saetta, MD, FCCP
Background: There is increasing evidence that matrix metalloproteinases (MMPs) may contribute
to the pathogenesis of COPD, but their role in humans is not completely understood. We
performed this study to quantify the expression of MMP-2 in a population of COPD patients at
different stages of severity.
Methods: We collected surgical specimens from 46 subjects, as follows: 10 smokers with severe
COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage III-IV); 13 smokers
with mild/moderate COPD (GOLD stage I-II); 12 control smokers; and 11 nonsmoking control
subjects. We quantified MMP-2 expression in alveolar macrophages, alveolar walls, peripheral
airways, and pulmonary arterioles by immunohistochemistry.
Results: In all compartments, MMP-2 expression was increased both in smokers with severe
COPD and in smokers with mild/moderate COPD compared to control smokers and nonsmokers
(p < 0.05 for all comparisons). Only in alveolar macrophages was MMP-2 expression increased in
smokers with severe COPD compared to smokers with mild/moderate COPD (p c0.002). More-
over, MMP-2 expression was inversely related to values of FEV1/FVC ratio (p< 0.0001; r0.71)
and PaO2 (in millimeters of Hg) [p 0.005; r0.49], and was positively related to emphysema
score (p 0.01; r 0.65) and residual volume percent predicted (p 0.04; r 0.49). A stepwise
increase in the total number of alveolar macrophages was observed in the four groups of subjects
examined, with the highest value in those with severe COPD.
Conclusion: This study shows that MMP-2 expression in the lung periphery progressively increases as
lung function worsens and the degree of emphysema increases. These results suggest that MMP-2
may be a key mediator of the mechanisms leading to lung tissue remodeling and inflammation in
patients with severe COPD. (CHEST 2007; 132:1733–1740)
Key words: airflow limitation; cigarette smoking; emphysema; extracellular matrix; inflammation
Abbreviations: GOLDGlobal Initiative for Chronic Obstructive Lung Disease; MMPmatrix metalloproteinase;
RV residual volume
COPD is a major clinical disorder that is usuallyassociated with cigarette smoking. The disease is
currently the fourth leading cause of death in the
world, and further increases in its prevalence and
mortality can be predicted in the coming decades.1
The defining feature of COPD is a chronic, slowly
progressive airflow limitation that results from the
combination of pulmonary emphysema and small
airways obstruction.
Inflammation, airway remodeling, and parenchy-
mal destruction are established features of COPD.2–4
Despite intensive research, the precise mechanisms
involved in the development and progression of
For editorial comment see page 1724
airflow limitation remain unclear. There is evidence
that the connective tissue plays an important role in
the homeostasis of the respiratory system by modu-
lating the activity of numerous cytokines and growth
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factors. It has therefore been proposed5 that alter-
ations in the connective tissue skeleton may repre-
sent an important step in the pathogenesis of em-
physema.
Matrix metalloproteinases (MMPs) are a large
family of zinc-dependent and calcium-dependent
proteolytic enzymes that are mainly derived from
macrophages and neutrophils, which can degrade
most of the components of the extracellular matrix.
Under normal physiologic conditions, they promote
remodeling of the extracellular matrix, thus facilitat-
ing cell migration, and are involved in immune
responses by cleaving the inactive forms of cytokines
and chemokines.6 Under pathologic conditions, a
switch in MMP expression and activity occurs, which
may lead to excessive lung inflammation and tissue
destruction.7,8
It is widely recognized that many MMPs are ex-
pressed in the human lung; however, very few studies
have addressed the direct quantification of these pro-
teases in lung tissue. When considering clinical and
animal studies together,9–21 there is compelling evi-
dence linking MMP-1, MMP-2, MMP-8, MMP-9, and
MMP-12 to emphysema. In particular, MMP-12 is
thought to be essential to cigarette smoke-induced
pathology in mouse disease,9,10 but may not be equally
critical in human disease.6,11 MMP-9 has been the
focus of interest with several studies12–19 reporting an
increase of this MMP in patients with COPD. Since
MMP-9 is largely produced by neutrophils, which
accumulate preferentially in the airway lumen rather
than in the tissue, it is better investigated in induced
sputum and BAL fluid.
MMP-2 belongs to the same gelatinase family as
MMP-9, but it has been less extensively studied in
COPD patients.14–17 MMP-2 is expressed by struc-
tural cells (ie, endothelial cells and smooth muscle
cells)22,23 as well as by macrophages and lympho-
cytes,24,25 which are the main cell types infiltrating
the lung tissue in COPD patients. In addition to
extracellular matrix degradation, MMP-2 may act as
a tuner and amplifier of the immune/inflammatory
response.26,27 In particular, there is evidence that
MMP-2 may amplify type 1 responses,28 and, in fact,
a predominant type 1 profile has been reported in
patients with COPD.29,30
We therefore decided to focus on MMP-2 because,
among MMPs, it is the one more likely to influence
inflammatory changes occurring specifically in the lung
tissue and to have direct effects on lung remodeling. To
quantify the expression of MMP-2 in patients with
COPD at different stages of disease severity, we exam-
ined surgically resected specimens from the following
four groups of subjects: smokers with severe COPD
(Global Initiative for Chronic Obstructive Lung Dis-
ease [GOLD] stage III-IV; n 10); smokers with
mild/moderate COPD (GOLD stage I-II; n 13);
asymptomatic smokers with normal lung function
(n 12); and asymptomatic nonsmoking subjects with
normal lung function (n 11). In these subjects,
MMP-2 expression was quantified by immunohisto-
chemistry in alveolar macrophages, in alveolar walls, in
peripheral airways, and in pulmonary arterioles.
Materials and Methods
Study Population
To quantify the expression of MMP-2, we collected lung tissue
from 46 subjects undergoing surgery for appropriate clinical
indications (ie, lung volume reduction surgery for the treatment
of severe emphysema or lung resection for a solitary peripheral
carcinoma). The subjects were categorized into the following four
groups: smokers with severe COPD (GOLD stage III-IV [ie,
FEV1/FVC ratio,  70%; FEV1,  50% predicted]; n  10);
smokers with mild/moderate COPD (GOLD stage I–II [ie,
FEV1/FVC ratio,  70%; FEV1,  50% predicted]; n  13);
asymptomatic smokers with normal lung function (n  12); and
asymptomatic nonsmoking subjects with normal lung function
(n  11).
Subjects with COPD did not experience any exacerbation, and
all recruited subjects had been free of acute upper respiratory
tract infections during the month preceding the study. The
subjects were nonatopic (ie, they had negative skin test results for
common allergen extracts), and had no history of asthma or
allergic rhinitis. The study conformed to the Declaration of
Helsinki, and informed written consent was obtained for each
subject undergoing surgery.
Clinical Assessment
Each patient underwent an interview, pulmonary function
tests, ECG, and routine blood tests in the week before surgery.
Pulmonary function tests were performed as previously de-
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scribed.31 Briefly, they included measurements of FVC, FEV1,
and, in a subset of 15 patients, complete pulmonary function tests
(ie, functional residual capacity, residual volume [RV], total lung
capacity, and diffusing capacity of the lung for carbon monoxide).
The predicted normal values used were those from the Commu-
nite´ Europeenne du Carbon e de l’Acier.32 In subjects with
normal lung function, inhalation challenge with methacholine
was performed, and all subjects had reactivity within the normal
range (provocative dose of methacholine causing a 20% fall in
FEV1,  1.44 mg).
Chest radiographs were obtained within 48 h of the lung
function studies. In a subset of 15 patients, scores for emphysema
were calculated on the basis of criteria for the evaluation of
roentgenographic signs of emphysema, as previously described.33
A detailed description is present in Web-only material.
Samples Collection and Analysis
Four to six randomly selected tissue blocks were taken from
the subpleural parenchyma at surgery (avoiding areas affected by
tumor in patients who underwent lung resection for carcinoma).
Samples were processed with immunohistochemical methods,
and MMP-2 expression was quantified in macrophages, alveolar
walls, peripheral airways, and pulmonary arterioles (see Web-
only material). Group data were expressed as the mean and SEM
or as the median and range where appropriate. Differences
between groups were analyzed using the nonparametric Kruskal-
Wallis U test for morphologic data, and analysis of variance for
clinical data. The Mann-Whitney U test was performed after the
Kruskal-Wallis test, where appropriate. Correlation coefficients
were calculated using the Spearman rank method. p Values of
 0.05 were accepted as significant.
Results
Table 1 shows the clinical characteristics of the
subjects examined. The complete analysis of clinical
and functional parameters is reported in Web-only
material.
As for MMP-2 immunoreactivity, a prominent stain-
ing was observed in alveolar macrophages and alveolar
walls (Fig 1), as well as in peripheral airways, and
pulmonary arterioles, where it was mainly associated
with smooth muscle bundles. The percentage of
MMP-2 macrophages differed significantly among
the four groups of subjects examined (p 0.0001) [Fig
2]. In particular, the percentage of MMP-2 macro-
phages was increased in smokers with severe COPD
when compared to smokers with mild/moderate
COPD (p 0.002), to control smokers (p 0.01), and
to nonsmokers (p 0.0001). The percentage of
MMP-2 macrophages was also increased in smokers
with mild/moderate COPD when compared to both
smoking and nonsmoking control subjects (p 0.03
and 0.001, respectively).
In alveolar walls, increased MMP-2 expression was
observed in smokers with severe COPD compared to
both smoking and nonsmoking control subjects
(p  0.008 and 0.02, respectively) [Fig 3]. Smokers
with severe COPD tended to have an increased
MMP-2 expression even when compared to smok-
ers with mild/moderate COPD, but this difference
did not reach the level of statistical significance
(p  0.07). Finally, smokers with mild/moderate
COPD had an expression of MMP-2 in alveolar
walls similar to that of smoking and nonsmoking
control subjects.
In bronchiolar smooth muscle, MMP-2 expres-
sion was increased to a similar degree in both
smokers with severe COPD (median, 2; range,
0.75 to 3) and smokers with mild/moderate COPD
(median, 2; range, 1 to 3) compared to control
smokers (median, 0.6; range, 0 to 3; p  0.03 and
0.01, respectively) and nonsmokers (median, 0.35;
range, 0 to 2.2; p  0.003 and 0.0008, respec-
tively). A similar pattern of expression was also
observed in the tunica media of pulmonary arte-
Table 1—Clinical Characteristics of the Patients*
Characteristics
Patients With
Severe COPD
Patients With Mild/
Moderate COPD Control Smokers Nonsmokers
Subjects examined, No.
Male 8 12 12 5
Female 2 1 0 6
Age, yr 63  3 65  2 63  2 62 4
Smoking history, pack-yr 48 9 47  5 45  7
FEV1, % predicted 33  3†‡ 73  4‡ 101  3 106  5
FEV1/FVC ratio, % 36  4†‡ 65  1‡ 78  2 79 1
Pao2, mm Hg 65  6†‡ 80  2 88  2 88 6
Paco2, mm Hg 40  2 41  1 41  3 38 1
Dlco, % predicted 30 5† 90  15
RV, % predicted 170 17† 94  15
Emphysema score 10 (7–15)† 5 (1–5.5)
*Values are given as the mean SEM or median (range), unless otherwise indicated.
†Significantly different from patients with mild/moderate COPD (p 0.005).
‡Significantly different from control smokers and nonsmokers (p 0.0001).
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rioles, with increased MMP-2 expression in both
smokers with severe COPD (median, 2.5; range, 1
to 3) and smokers with mild/moderate COPD
(median, 2.5; range, 0 to 3) compared to control
smokers (median, 1.3; range, 0.25 to 2.5;
p  0.005 and 0.01, respectively) and nonsmokers
(median, 1; range, 0 to 2; p  0.001 and 0.008,
respectively).
Figure 1. Microphotograph showing MMP-2 staining (in red) in lung tissue from a smoker with severe
COPD (top left, a), a smoker with mild/moderate COPD (bottom left, b), a control smoker (top center,
c), and a nonsmoker (bottom center, d). [original 630]. Representative examples of MMP-2 staining
in peripheral airways (top right, e) and pulmonary arterioles (bottom right, f) from a smoker with severe
COPD (original 200). Arrowheads indicate the specific immunostaining as identified with the
monoclonal antibody antihuman MMP-2 (Calbiochem; San Diego, CA).
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Figure 2. Individual counts for the percentage of MMP-2
macrophages (over total macrophages) in smokers with severe
COPD, smokers with mild/moderate COPD, control smokers, and
nonsmokers. Horizontal bars represent median values. The p values
represent the results of Mann-Whitney U test analyses. Overall
comparison was made using the Kruskal-Wallis test (p 0.0001).
M
M
P
-2
Figure 3. Individual counts for the number of MMP-2 cells in
alveolar walls in smokers with severe COPD, smokers with
mild/moderate COPD, control smokers, and nonsmokers. Hori-
zontal bars represent median values. The p values represent the
results of Mann-Whitney U test analyses. Overall comparison was
made using the Kruskal-Wallis test (p 0.05).
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In none of the compartments examined was
MMP-2 expression different between smokers
with normal lung function and nonsmoking control
subjects. The expression of MMP-2 was not influ-
enced by current smoking status and was not
correlated with cumulative smoking history.
The total number of macrophages in alveolar
spaces increased stepwise. Indeed, the macro-
phage score was significantly increased in smokers
with severe COPD (median, 2; range, 0.5 to 3)
compared to smokers with mild/moderate COPD (me-
dian, 1; range, 0.3 to 2; p 0.01), to control smokers
(median, 0.5; range, 0.2 to 1.5; p 0.0005), and to
nonsmokers (median, 0.3; range, 0.2 to 0.5;
p 0.0001). The macrophage score was also signifi-
cantly increased in smokers with mild/moderate COPD
compared to control smokers (p 0.02) and nonsmok-
ers (p 0.0006). Finally, the macrophage score was
significantly increased in control smokers compared to
nonsmokers (p 0.04).
Considering all smokers as one group, the per-
centages of MMP2 macrophages were inversely
related to the values of FEV1 percent predicted
(p  0.0001; r  0.66) [Fig 4], FEV1/FVC ratio
(p  0.0001; r  0.71), and Pao2 millimeters of
Hg (p  0.005; r  0.49). Moreover, the num-
ber of MMP2 cells in alveolar walls was inversely
related to the values of FEV1 percent predicted
(p 0.05; r0.33) and FEV1/FVC ratio (p 0.01;
r0.42). Finally, even in peripheral airways, MMP-2
expression was inversely related to the value of FEV1/
FVC ratio (p 0.02; r0.43), while in pulmonary
arterioles it was related to values of both FEV1/FVC ratio
(p 0.007; r0.46) and Pao2 millimeters of Hg
(p 0.03; r0.35).
When the analysis was limited to smokers with
COPD, the only correlations to remain significant
were those between the percentages of MMP2
macrophages and FEV1 percent predicted (p 0.01;
r0.53) or FEV1/FVC ratio (p 0.003; r0.62).
In the subset of patients in whom complete pulmonary
function test results and radiologic scores of emphysema
were determined, the percentages of MMP2 macro-
phages were positively correlated with the values of
residual volume (p 0.04; r 0.49) and emphysema
score (p 0.01; r 0.65) [Fig 5].
Discussion
This study shows that in patients with COPD there
is a marked up-regulation of MMP-2 in the lung
periphery that is related to the degree of lung
function impairment and emphysema. These results
suggest that MMP-2 may be a key mediator of the
mechanisms leading to lung tissue destruction in
patients with severe COPD.
A number of animal models have illustrated the
potential role of MMPs in the development of em-
physema. In guinea pigs, exposure to cigarette smoke
produces emphysematous changes that are associated
with increased levels of collagenase messenger RNA,
resulting in collagen loss.34 In mice exposed to cigarette
smoke, the lack of MMP-12 activity prevents emphy-
sema development and macrophage infiltration.9,10 In
humans, an analysis of protease production by alveolar
macrophages in vitro has shown an increased expres-
sion of MMP-9 and MMP-12 in subjects with emphy-
sema.12,13,35 However, studies of alveolar macrophages
in culture have raised questions about the relationship
of these findings to what is actually occurring in vivo, a
limitation that may be overcome with the direct analysis
of lung tissue.
Our study has provided evidence of MMP-2 up-
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Figure 4. Relationship between the values of FEV1 (percent
predicted [% pred]) and the percentage of MMP-2 macro-
phages in all of the smoking subjects included in the study.
Spearman rank correlation yield p  0.0001 and r  0.66. The
correlation remained significant when only smokers with COPD
were considered (p  0.01; r  0.53).
MMP-2
Figure 5. Relationship between the values of emphysema score
and the percentage of MMP-2 macrophages in the subset of
patients in whom a radiologic evaluation of emphysema was
performed. Spearman rank correlation yielded p 0.01 and
r  0.65.
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regulation within the lung tissue in a population of
smokers with COPD at different stages of disease
severity, extending the findings of previous re-
ports14,15 that examined smaller groups of subjects
with a narrow range of airflow limitation. Moreover,
by performing immunohistochemical analysis on
morphologically preserved lung samples, we could
quantify MMP-2 in the different compartments of
the lung. Unfortunately, we could not directly mea-
sure enzyme activity and, therefore, correlate it with
MMP-2 content. Of interest, Ohnishi and cowork-
ers,15 who analyzed frozen samples from patients
with emphysema, found that the increase in MMP-2
content was paralleled by a significant increase in
enzyme activity. The authors15 suggested that the
increased MMP-2 expression, which was related to
increased proteolytic activity, may significantly contrib-
ute to the destruction of the alveolar walls. This hy-
pothesis is supported by the significant correlation
observed in our study between MMP-2 expression and
the degree of radiologic evidence of emphysema.
In our study, immunostaining for MMP-2 was
more prominent in alveolar macrophages than in all
the other compartments examined. At variance with
the traditional view,36,37 there is recent evidence that
macrophages have the ability to produce MMP-2 in
vitro25 and our observations suggest that they may do
so in vivo as well. It should be highlighted however
that, even if we are assuming that most of the
immunoreactivity is due to endogenous MMP-2, we
cannot rule out the possibility that some may be due
to extracellular MMP-2 sequestered by macro-
phages. Of interest in our own, as well as in previous
reports,38,39 the total number of macrophages signif-
icantly increases as COPD progresses toward the most
severe stages. The combination of this remarkable
macrophage expansion and MMP-2 up-regulation
must result in a dramatic increase in proteolytic
activity, which may account for tissue destruction.
Of note, MMPs may also be involved in orches-
trating the amplification of the inflammatory re-
sponse, which occurs in the lung tissue of smokers
with severe COPD.4,38,39 For example, it has been
suggested28 that an unrestrained expression of MMP-2
may contribute to the aberrant type 1 immune re-
sponse that promotes tissue destruction in autoimmune
diseases. This observation is particularly relevant to the
present study, since an increased type 1 response has
been reported in patients with COPD,29,30 and COPD
has been proposed to be an autoimmune disorder in
which the aberrant response is driven by the products
of proteolytic activity.40–42
It is presently unclear what cell type is driving the
degradation of the extracellular matrix in patients
with emphysema. In our study, we examined MMP-2
expression by alveolar macrophages; however, we
cannot rule out the possibility that other inflamma-
tory cells may also be involved. In particular, lym-
phocytes, which are increased in the alveolar walls of
smokers with COPD,43,44 and neutrophils, which are
abundant in patients with more advanced stages of
the disease,45 can secrete a wide array of proteases.
Finally, even lung structural cells may secrete
MMPs; indeed, in our study the great majority of the
MMP-2 expression within peripheral airways and
pulmonary arterioles was not observed in inflamma-
tory cells (as it was in the alveolar compartment), but
was mainly associated with smooth muscle cells.
Increased smooth muscle mass is one of the most
important pathologic lesions observed in the periph-
eral airways of smokers with COPD, where it may
contribute to airway wall thickening and, therefore,
to the development of airflow limitation. Evidence
has been gathered23 that human airway smooth
muscle cells can secrete MMP-2 and that the inhi-
bition of this MMP reduces airway smooth muscle
proliferation. These observations support the hy-
pothesis that MMP-2 may have an important role in
the progression of airflow limitation. Conversely,
whether the presence of airway obstruction itself
could influence the retention of MMP-2 in the
airway wall still remains to be investigated.
It is noteworthy that, in our study, although to-
bacco smoking enhanced the recruitment of macro-
phages to the alveolar spaces, it did not affect
MMP-2 expression. Indeed, this protease was not
up-regulated in smokers with normal lung function
compared to nonsmoking control subjects. Further-
more, the expression of MMP-2 was not influenced
by current smoking status or cumulative smoking
history, suggesting that smoking per se did not
influence MMP-2 expression. This scenario is differ-
ent from that observed in animal models, where
exposure to tobacco smoke was sufficient to induce
MMPs, and raises the hypothesis that up-regulation
of MMP-2 in humans is not a response to cigarette
smoking in general, but is strictly related to the
presence of COPD.
Of interest, it has been shown that MMP-2 is
involved in the pathogenesis of lung cancer, which is
a frequent comorbidity in patients with COPD,46,47
by promoting tumor invasion and metastasis.48,49
While it is true that the presence of lung cancer in
some of our patients may have influenced the results,
we tried to avoid this bias by collecting lung tissue
from areas not affected by tumor and by having
included subjects with lung cancer in the control
groups. Furthermore, since the highest MMP-2 ex-
pression was observed in the group without concom-
itant cancer (ie, smokers with severe COPD under-
going lung volume reduction surgery), we feel rather
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confident that our findings of an increased MMP-2
expression in COPD patients are valid.
Another potential limitation of our report is the
low power of the study because of the small number
of subjects in each group. Although we cannot
exclude the possibility of a type 2 statistical error (ie,
the inability to detect subtle differences between
groups), we are rather confident that the significant
differences observed were not influenced by the
relatively small size of our groups. Moreover, we
should acknowledge that, in our study, some of the
MMP-2 content may have been masked by binding
to other proteins, such as tissue inhibitors of metal-
loproteinases. However, previous reports50 as well as
our experience in Western blot experiments, suggest
that anti-MMP-2 antibodies identify not only free
MMP-2, but also MMP-2/tissue inhibitor of metal-
loproteinase complexes, which are not completely
dissociated by sodium dodecyl sulfate.
In conclusion, in patients with COPD, MMP-2
expression in the lung periphery is progressively
enhanced as lung function worsens and the degree of
emphysema increases. These observations suggest
that MMP-2 may have a crucial role in the develop-
ment and progression of COPD, possibly by promot-
ing parenchymal destruction and the remodeling of
airways and vasculature.
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